Chimerix, Inc. (NASDAQ:CMRX) Sees Significant Drop in Short Interest

Chimerix, Inc. (NASDAQ:CMRX - Get Free Report) was the target of a large decline in short interest in August. As of August 15th, there was short interest totalling 1,690,000 shares, a decline of 10.6% from the July 31st total of 1,890,000 shares. Based on an average trading volume of 485,300 shares, the days-to-cover ratio is presently 3.5 days. Approximately 2.1% of the shares of the stock are short sold.

Institutional Investors Weigh In On Chimerix

A number of institutional investors have recently made changes to their positions in CMRX. Marshall Wace LLP bought a new position in Chimerix during the second quarter worth about $137,000. Acadian Asset Management LLC grew its holdings in Chimerix by 15.5% during the first quarter. Acadian Asset Management LLC now owns 2,174,813 shares of the biopharmaceutical company's stock valued at $2,304,000 after purchasing an additional 291,981 shares during the period. Koshinski Asset Management Inc. acquired a new position in Chimerix during the first quarter valued at approximately $42,000. Marquette Asset Management LLC increased its stake in Chimerix by 24.3% in the first quarter. Marquette Asset Management LLC now owns 116,009 shares of the biopharmaceutical company's stock valued at $123,000 after purchasing an additional 22,709 shares in the last quarter. Finally, Pale Fire Capital SE raised its holdings in Chimerix by 113.6% in the fourth quarter. Pale Fire Capital SE now owns 211,214 shares of the biopharmaceutical company's stock worth $203,000 after purchasing an additional 112,318 shares during the period. 45.42% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. Wedbush reaffirmed an "outperform" rating and set a $6.00 price target on shares of Chimerix in a report on Tuesday, August 13th. StockNews.com raised shares of Chimerix from a "sell" rating to a "hold" rating in a report on Wednesday, August 21st. Finally, HC Wainwright reissued a "buy" rating and issued a $11.00 price target on shares of Chimerix in a report on Wednesday, August 14th.

Chimerix Stock Performance

Chimerix stock traded down $0.01 during trading hours on Friday, reaching $0.93. 123,523 shares of the company's stock traded hands, compared to its average volume of 1,092,528. Chimerix has a fifty-two week low of $0.75 and a fifty-two week high of $1.30. The firm's 50 day moving average is $0.90 and its 200-day moving average is $0.97. The firm has a market capitalization of $83.55 million, a price-to-earnings ratio of -1.00 and a beta of 1.20.

Chimerix (NASDAQ:CMRX - Get Free Report) last announced its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.23). The firm had revenue of $0.13 million for the quarter, compared to analysts' expectations of $1.26 million. Chimerix had a negative net margin of 25,337.96% and a negative return on equity of 46.35%. During the same period last year, the firm earned ($0.21) earnings per share. Analysts predict that Chimerix will post -0.86 EPS for the current year.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.